Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. develops telitacicept for autoimmune diseases, with company updates centered on clinical development, financing, governance and employee equity compensation. Telitacicept is described by the company as a dual BAFF/APRIL inhibitor and novel dual-target fusion protein for autoantibody-driven conditions, with global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease.
Recurring news includes clinical-trial starts and data discussions, financial results and balance-sheet updates, private-placement financing, board appointments, investor-conference presentations and Nasdaq inducement grants under the Vor Biopharma Inc. 2023 Inducement Plan. Company announcements also reflect telitacicept regulatory status in China and global development across major autoimmune indications.
Vor Bio (Nasdaq: VOR) reported second-quarter 2024 financial results and a corporate update. The company is advancing in its trem-cel + Mylotarg and VCAR33ALLO clinical trials. Trem-cel, aimed at AML and MDS patients, is progressing with 21 patients dosed, with the third dose level of Mylotarg at 2.0 mg/m2. Data updates, including engraftment, hematologic protection, and pharmacokinetic analyses, are expected in H2 2024. VCAR33ALLO is also advancing, with several patients dosed and initial data expected in H2 2024. Financially, Vor Bio ended Q2 2024 with $85.9 million in cash, projected to fund operations into H2 2025. R&D expenses decreased to $21.8 million from $23.9 million YoY, and G&A expenses decreased to $7.2 million from $8.3 million YoY. Net loss narrowed to $27.8 million from $30.0 million YoY.
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced inducement grants for a newly hired employee. The grants, approved by the Compensation Committee, include stock options to purchase 1,250 shares and restricted stock units (RSUs) for 1,875 shares of Vor Bio's common stock. These grants were made under the Vor Biopharma Inc. 2023 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The stock options have a ten-year term and an exercise price of $0.929 per share, equal to the closing price on July 31, 2024. Both options and RSUs will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly (options) or quarterly (RSUs) over the following 36 months, subject to continued employment.
Vor Bio (Nasdaq: VOR) announced on July 9, 2024, the issuance of stock options and restricted stock units (RSUs) to three new employees. Effective July 1, 2024, these grants are material inducements to employment under Nasdaq Listing Rule 5635(c)(4). The granted options allow for the purchase of 3,000 shares at $0.92 per share, the closing price on July 3, 2024, and have a ten-year term. Vesting occurs over four years, with 25% after 12 months and monthly thereafter. The RSUs cover 4,500 shares, also vesting over four years, with 25% after 12 months and quarterly thereafter. These grants follow the Vor Biopharma 2023 Inducement Plan.
Vor Bio, a clinical-stage cell and genome engineering company, announced that on June 1, 2024, the Compensation Committee of the Board of Directors granted stock options and restricted stock units (RSUs) to a new employee. The inducement grant includes 1,000 stock options and 1,500 RSUs under the Vor Biopharma 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term, an exercise price of $1.41 per share, and will vest over four years. The RSUs will also vest over four years with a similar vesting schedule.
Vor Bio reported strong financial results for the first quarter of 2024 and provided updates on its clinical trials. The company is making progress with its VCAR33ALLO and trem-cel trials, expanding to include patients with myelodysplastic syndromes (MDS) and advancing Mylotarg dosing. Vor Bio also welcomed a new Board member and highlighted upcoming milestones. The company's cash position is healthy, with $107.5 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
Vor Bio, a clinical-stage cell and genome engineering company, will participate in upcoming investor conferences, including Citizens JMP Life Sciences Conference and H.C. Wainwright 2nd Annual BioConnect Investor Conference. The company aims to engage with investors and showcase its progress and potential.
Vor Bio granted stock options and restricted stock units to six newly hired employees as inducements to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options and RSUs have a ten-year term, with vesting over a four-year period based on continued employment.
Vor Bio appointed Fouad Namouni, M.D., an accomplished oncology and cancer immunotherapy R&D executive, to its Board of Directors. Dr. Namouni brings over 20 years of industry experience to Vor Bio, having served as President of Research & Development at Blueprint Medicines. His expertise in clinical development and regulatory affairs will be important as Vor Bio advances its approach to curing acute myeloid leukemia.
Summary not available.
Summary not available.